JP Morgan: raises Aier Eye Hospital (06855) target price to HK$93, rated as "buy"

JP Morgan released a research report stating that BeiGene (Hong Kong) Co., Ltd. (06855) stock has accumulated a year-to-date increase of approximately 83%, in line with the strong performance of the Hang Seng Healthcare Index (a year-to-date increase of about 78%). Following discussions with management at a recent Sino-US biotechnology forum and considering the latest developments in the company's product pipeline, JP Morgan updated its model. JP Morgan included more optimistic sales estimates for the products, raising the target price for BeiGene from the original HK$52 to HK$93, an increase of 79%; maintaining an overweight rating. JP Morgan continues to have a positive outlook on the company's key assets "olverembatinib" and "lisaftoclax", expecting them to drive strong product sales this year. JP Morgan has also raised its outlook for the overseas potential of "lisaftoclax", particularly considering that "venetoclax" did not demonstrate an overall survival benefit in myelodysplastic syndromes (MDS), and the market approval scope for the drug in China exceeded expectations.